BioCurex Wins Australian Patent on Therapeutic Applications for RECAF Marker
Posted on: Friday, 19 September 2008, 09:00 CDT
BioCurex, a biotechnology company, has announced that the Australian Patent Office has issued a notice of acceptance for a divisional application of its original patent filing. This is said to be the first patent awarded to BioCurex for the development of therapeutic applications of its RECAF technology.
The original filing contained claims related to both diagnostics and therapeutics. During the reviewing process, the mixed nature of the claims resulted in a split (technically known as a divisional application) of the claims in two separate patent files while maintaining the original date.
The diagnostic patent application was granted by the Australian Patent Office before and now, the divisional containing the claims for therapeutic applications have also been approved.
BioCurex has proprietary technology on the uses of a molecule called RECAF that is present on the surface and inside cancer cells - though which are mostly absent from healthy cells as well as benign tumor cells. Cancer cells release some RECAF into the blood stream and this has allowed the company to develop a blood test for cancer that detects approximately 90% of patients with malignancies at the standard specificity of 95% (5% false positives).
The presence of RECAF also on the surface of malignant cells allows for the specific targeting of a cancer. That is, there is no collateral damage to healthy cells known as 'side effects' produced by traditional chemotherapy, the company said.
BioCurex has already secured licenses for its diagnostic tests with Abbott Labs (ABT) and Inverness Medical Innovations (IMA) and is currently working on therapeutic applications, an initiative that will be largely expanded once the diagnostic applications are marketed.
Source: Datamonitor
Related Articles
- Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
- Cell Therapeutics, Inc. (CTI) Receives SPA Approval From FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- First Patient Enrolled in Point Therapeutics' Second Phase 3 Clinical Trial in Metastatic Non-Small Cell Lung Cancer
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Point Therapeutics Announces Positive Results at AACR-EORTC-NCI Conference From Phase 2 Talabostat Non-Small Cell Lung Cancer Study
- Point Therapeutics Initiates Phase 3 Program in Metastatic Non-Small Cell Lung Cancer
- Point Therapeutics Presents Positive Results in Phase 2 Talabostat Non-Small Cell Lung Cancer Study
- Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients With Non-Small Cell Lung Cancer
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
 |
 |
User Comments (0)
RSS Feeds